St Vincents Hospital And Institute

Melbourne, Australia

St Vincents Hospital And Institute

Melbourne, Australia
SEARCH FILTERS
Time filter
Source Type

Villemagne Sanchez L.A.,University of Melbourne | Villemagne Sanchez L.A.,Peter MacCallum Cancer Center | O'Callaghan C.,University of Melbourne | O'Callaghan C.,Peter MacCallum Cancer Center | And 12 more authors.
Leukemia and Lymphoma | Year: 2017

Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81% of participants (95% CI: 72%–89%) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest motivations for TFR included TKI toxicity (n = 26) and convenience (n = 18). The leading reason for reluctance was fear of consequences of stopping TKI (n = 16). Reluctance was often associated with needs for additional information or incomplete understanding of the current data. Understanding patient motivations and concerns is important if TFR is to become a part of CML management. © 2017 Informa UK Limited, trading as Taylor & Francis Group

Loading St Vincents Hospital And Institute collaborators
Loading St Vincents Hospital And Institute collaborators